脐带间充质干细胞治疗中晚期博来霉素诱导小鼠肺间质纤维化的机制

doi:10.6040/j.issn.1671-7554.0.2023.0092

摘要/Abstract

摘要： 目的观察脐带间充质干细胞(MSCs)对中晚期肺间质纤维化的治疗效果。方法将39只雄性昆明小鼠随机分为3组,分别为正常对照组(NC组)12只,博莱霉素组(PC组)12只,MSCs组15只;第1天PC组及MSCs组小鼠气管内注入博来霉素,NC组小鼠气管内注入等量生理盐水,21 d后MSCs组随机解剖3只小鼠,同时剩余小鼠尾静脉注入MSCs,第42天处死小鼠,比较3组小鼠肺湿重、羟脯氨酸及转化生长因子-β(TGF-β)、干扰素-γ(IFN-γ)等因子的表达情况。结果第21天MSCs组小鼠肺泡纹理紊乱,肺泡间隔增宽,肺间质纤维化形成。第42天NC组小鼠肺泡纹理清晰,无肺泡间隔增宽现象;PC组小鼠肺泡纹理紊乱,间隔明显增宽;MSCs组小鼠肺泡纹理较清晰,肺泡间隔增宽。PC组肺湿重、羟脯氨酸含量及TGF-β表达均明显高于NC组(P<0.01)及MSCs组(P<0.05);MSCs组IFN-γ表达明显高于PC组(P<0.01),PC组IFN-γ表达明显高于NC组(P<0.01)。结论 MSCs可以保护肺组织,抑制和减轻小鼠中晚期肺间质纤维化形成。

关键词: 脐带间充质干细胞, 博来霉素, 肺间质纤维化, 治疗效果

Abstract: Objective To explore the therapeutic effects of umbilical cord mesenchymal stem cells(MSCs)on advanced pulmonary fibrosis. Methods A total of 39 male Kunming mice were randomly divided into 3 groups: normal control group(n=12, NC group), bleomycin group(n=12, PC group)and MSCs treatment group(n=15, MSCs group). On day 1, bleomycin was injected into the trachea of mice in the PC and MSCs groups, and the same amount of saline was injected into mice in the NC group. On day 21, 3 mice in the MSCs group were dissected and the other mice were injected with MSCs into the tail vein. On day 42, all mice were sacrificed. The lung wet weight, hydroxyproline and the expression of transforming growth factor beta(TGF-β)and interferon-gamma(IFN-γ)were compared among the 3 groups. Results On day 21, the alveolar texture was disordered in the MSCs group, the alveolar interval was widened, and the pulmonary interstitial fibrosis was formed. On day 42, the alveolar texture was visible in the NC group and there was no alveolar interval widening; the alveolar texture was disordered in the PC group and the interval was significantly widened; the alveolar texture was clear in the MSCs group, and the alveolar interval was widened. The PC group had significantly higher lung wet weight, hydroxyproline content and TGF-β expression than the NC group(P<0.01)and MSCs group(P<0.05). The MSCs group had significantly higher IFN-γ expression than the PC group(P<0.01), followed by the NC group(P<0.01). Conclusion MSCs can protect lung tissue, and inhibit and alleviate the formation of intermediate and late pulmonary interstitial fibrosis in mice.

Key words: Umbilical cord mesenchymal stem cells, Bleomycin, Pulmonary interstitial fibrosis, Therapeutic effect

中图分类号:

R563

王成,张淑卉,闫娜,孟林林,陈良志,刘庆华. 脐带间充质干细胞治疗中晚期博来霉素诱导小鼠肺间质纤维化的机制[J]. 山东大学学报 (医学版), 2023, 61(10): 17-22.

WANG Cheng, ZHANG Shuhui, YAN Na, MENG Linlin, CHEN Liangzhi, LIU Qinghua. Mechanism of umbilical cord mesenchymal stem cells treating bleomycin-induced pulmonary interstitial fibrosis in mice[J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 17-22.

参考文献

[1] Mirzaei H, Sahebkar A, Shiri LS, et al. Therapeutic application of multipotent stem cells [J]. J Cell Physiol, 2017, 233(4): 2815-2823.
[2] Ghionzoli M, Cananzi M, Zani A, et al. Amniotic fluid stem cell migration after intraperitoneal injection in pup rats: implication for therapy [J]. Pediatr Surg Int, 2010, 26(1): 79-84.
[3] 顾盼, 罗本芳, 易祥华, 等. 特发性肺纤维化和特发性非特异性间质性肺炎中细胞因子的表达及分析[J]. 中华结核和呼吸杂志, 2014, 37(9): 664-670. GU Pan, LUO Benfang, YI Xianghua, et al. The expressions and meanings of BMP-7 and TGF-β in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2014, 37(9): 664-670.
[4] 谯智慧, 张丹, 熊玮. 8例临床级脐带间充质干细胞治疗放射性肺纤维化的观察[J].第三军医大学学报, 2017, 39(10): 1013-1018. QIAO Zhihui, ZHANG Dan, XIONG Wei. Efficacy and safety of clinical-grade umbilical cord mesenchymal stem cell therapy for treatment of radiation-induced pulmonary fibrosis: analysis of 8 cases [J]. Acta Academiae Medicinae Militaris Tertiae [J]. 2017, 39(10): 1013-1018.
[5] Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis [J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(2): L152-L160.
[6] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer(LUME-Lung 1): a phase 3, double-blind, randomised controlled trial [J]. Lancet Oncol, 2014, 15(2): 143-155.
[7] Zhou MI, Chen D, Jiang T, et al. Effects of bone marrow-derived mesenchymal stem cells transfected with survivin on pulmonary fibrosis in mice [J]. Exp Ther Med, 2015, 10(5): 1857-1864.
[8] Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina [J].Chin Med Sci J, 2006, 21(3): 145-151.
[9] Yan X, Liu Y, Han Q, et al. Injured microenvironment directly guides the differentiation of engrafted Flk-1+ mesenchymal stem cell in lung [J]. Exp Hematol, 2007, 35(9): 1466-1475.
[10] Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure [J]. Am J Respir Crit Care Med, 1994, 150(3): 670-675.
[11] Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis [J]. Lancet, 1996, 347(8997): 284-289.
[12] Li H. The diagnosis and treatment of idiopathic pulmonary fibrosis [J]. Dtsch Arztebl Int, 2013, 110(51-52): 875-881.
[13] León-Román F, Valenzuela C, Molina-Molina M. Idiopathic pulmonary fibrosis. Fibrosis pulmonar idiopática [J]. Med Clin(Barc), 2022, 159(4): 189-194.
[14] 曹孟淑, 蔡后荣, 代华平. 2015ATS/ERS/JRS/ALAT官方的临床实践指南:特发性肺纤维化的治疗(执行摘要)——对2011年临床指南的更新[J]. 中国呼吸与危重监护杂志, 2016, 15(2): 189-197.
[15] Collard HR, Yow E, Richeldi L, et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials [J]. Respir Res, 2013, 14(1): 73. doi: 10.1186/1465-9921-14-73.
[16] Ghionzoli M, Cananzi M, Zani A, et al. Amniotic fluid stem cell migration after intraperitoneal injection in pup rats: implication for therapy [J]. Pediatr Surg Int, 2010, 26(1): 79-84.
[17] Kurtz A. Mesenchymal stem cell delivery routes and fate [J]. Int J Stem Cells, 2008, 1(1): 1-7.
[18] Xiong M, Tao Y, Gao Q, et al. Human stem cell-derived neurons repair circuits and restore neural function [J]. Cell Stem Cell, 2020, 28(1): 112-126.
[19] Sneddon JB, Tang Q, Stock P, et al. stem cell therapies for treating diabetes: progress and remaining challenges [J]. Cell Stem Cell, 2018, 22(6): 810-823.
[20] 马仕芹, 代华平, 陈颖, 等. 特发性肺纤维化患者血清及支气管肺泡灌洗液中转化生长因子-β和Ⅲ型前胶原含量变化的关系[J]. 医学理论与实践, 2004, 17(8): 873-875. MA Shiqin, DAI Huaping, CHEN Ying, et al. Study on relationship between transforming growth factor-β and procollagen III in peripheral blood and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis [J]. The Journal of Medical Theory and Practice, 2004, 17(8): 873-875.
[21] Chu KA, Wang SY, Yeh CC, et al. Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Whartons jelly [J]. Theranostics, 2019, 9(22): 6646-6664.
[22] Yan X, Liu Y, Han Q, et al. Injured microenvironment directly guides the differentiation of engrafted Flk-1(+)mesenchymal stem cell in lung [J]. Exp Hematol, 2007, 35(9): 1466-1475.
[23] Sumida A, Hasegawa Y, Okamoto M, et al. Th1/Th2 immune response in lung fibroblasts in interstitial lung disease [J]. Arch Med Res, 2008, 39(5): 503-510.
[24] Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement [J]. Eur Respir J, 2009, 33(4): 882-896.
[25] Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina [J]. Chin Med Sci J, 2006, 21(3): 145-151.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed